BACKGROUND: Preclinical and epidemiologic studies suggest chemopreventive effects of green tea (GT) and black tea (BT) in prostate cancer. In the current study we determined the effect of GT and BT consumption on biomarkers related to prostate cancer development and progression. METHODS: In this exploratory, open label, phase II trial 113 men diagnosed with prostate cancer were randomized to consume six cups daily of brewed GT, BT or water (control) prior to radical prostatectomy (RP). The primary endpoint was prostate tumor markers of cancer development and progression determined by tissue immunostaining of proliferation (Ki67), apoptosis (Bcl-2, Bax, Tunel), inflammation (nuclear and cytoplasmic nuclear factor kappa B [NFκB]) and oxidation (8-hydroxydeoxy-guanosine [8OHdG]). Secondary endpoints of urinary oxidation, tea polyphenol uptake in prostate tissue, and serum prostate specific antigen (PSA) were evaluated by high performance liquid chromatography and ELISA analysis. RESULTS: Ninety three patients completed the intervention. There was no significant difference in markers of proliferation, apoptosis and oxidation in RP tissue comparing GT and BT to water control. Nuclear staining of NFκB was significantly decreased in RP tissue of men consuming GT (P = 0.013) but not BT (P = 0.931) compared to water control. Tea polyphenols were detected in prostate tissue from 32 of 34 men consuming GT but not in the other groups. Evidence of a systemic antioxidant effect was observed (reduced urinary 8OHdG) only with GT consumption (P = 0.03). GT, but not BT or water, also led to a small but statistically significant decrease in serum prostate-specific antigen (PSA) levels (P = 0.04). CONCLUSION: Given the GT-induced changes in NFκB and systemic oxidation, and uptake of GT polyphenols in prostate tissue, future longer-term studies are warranted to further examine the role of GT for prostate cancer prevention and treatment, and possibly for other prostate conditions such as prostatitis.
RCT Entities:
BACKGROUND: Preclinical and epidemiologic studies suggest chemopreventive effects of green tea (GT) and black tea (BT) in prostate cancer. In the current study we determined the effect of GT and BT consumption on biomarkers related to prostate cancer development and progression. METHODS: In this exploratory, open label, phase II trial 113 men diagnosed with prostate cancer were randomized to consume six cups daily of brewed GT, BT or water (control) prior to radical prostatectomy (RP). The primary endpoint was prostate tumor markers of cancer development and progression determined by tissue immunostaining of proliferation (Ki67), apoptosis (Bcl-2, Bax, Tunel), inflammation (nuclear and cytoplasmic nuclear factor kappa B [NFκB]) and oxidation (8-hydroxydeoxy-guanosine [8OHdG]). Secondary endpoints of urinary oxidation, teapolyphenol uptake in prostate tissue, and serum prostate specific antigen (PSA) were evaluated by high performance liquid chromatography and ELISA analysis. RESULTS: Ninety three patients completed the intervention. There was no significant difference in markers of proliferation, apoptosis and oxidation in RP tissue comparing GT and BT to water control. Nuclear staining of NFκB was significantly decreased in RP tissue of men consuming GT (P = 0.013) but not BT (P = 0.931) compared to water control. Teapolyphenols were detected in prostate tissue from 32 of 34 men consuming GT but not in the other groups. Evidence of a systemic antioxidant effect was observed (reduced urinary 8OHdG) only with GT consumption (P = 0.03). GT, but not BT or water, also led to a small but statistically significant decrease in serum prostate-specific antigen (PSA) levels (P = 0.04). CONCLUSION: Given the GT-induced changes in NFκB and systemic oxidation, and uptake of GT polyphenols in prostate tissue, future longer-term studies are warranted to further examine the role of GT for prostate cancer prevention and treatment, and possibly for other prostate conditions such as prostatitis.
Authors: Bridget N Fahy; Michael G Schlieman; Melinda M Mortenson; Subbulakshmi Virudachalam; Richard J Bold Journal: Cancer Chemother Pharmacol Date: 2005-03-25 Impact factor: 3.333
Authors: Susanne M Henning; William Aronson; Yantao Niu; Francisco Conde; Nicolas H Lee; Navindra P Seeram; Ru-Po Lee; Jinxiu Lu; Diane M Harris; Aune Moro; Jenny Hong; Leung Pak-Shan; R James Barnard; Hossein G Ziaee; George Csathy; Vay L W Go; Hejing Wang; David Heber Journal: J Nutr Date: 2006-07 Impact factor: 4.798
Authors: Imtiaz A Siddiqui; Najia Zaman; Moammir H Aziz; Shannon R Reagan-Shaw; Sami Sarfaraz; Vaqar M Adhami; Nihal Ahmad; Sheikh Raisuddin; Hasan Mukhtar Journal: Carcinogenesis Date: 2005-12-29 Impact factor: 4.944
Authors: Christopher Sweeney; Lang Li; Rajasubramaniam Shanmugam; Poornima Bhat-Nakshatri; Vetrichelvan Jayaprakasan; Lee Ann Baldridge; Thomas Gardner; Martin Smith; Harikrishna Nakshatri; Liang Cheng Journal: Clin Cancer Res Date: 2004-08-15 Impact factor: 12.531
Authors: Zhenzhen Zhang; Mark Garzotto; Tomasz M Beer; Philippe Thuillier; Stephen Lieberman; Motomi Mori; Wesley A Stoller; Paige E Farris; Jackilen Shannon Journal: Nutr Cancer Date: 2016-09-20 Impact factor: 2.900
Authors: Sam F Peisch; Erin L Van Blarigan; June M Chan; Meir J Stampfer; Stacey A Kenfield Journal: World J Urol Date: 2016-08-12 Impact factor: 4.226
Authors: Gagan Chhabra; Chandra K Singh; Mary Ann Ndiaye; Samantha Fedorowicz; Arielle Molot; Nihal Ahmad Journal: Cancer Lett Date: 2018-02-20 Impact factor: 8.679
Authors: Piwen Wang; Susanne M Henning; Clara E Magyar; Yahya Elshimali; David Heber; Jaydutt V Vadgama Journal: J Exp Clin Cancer Res Date: 2016-05-06
Authors: Sandaly O S Pacheco; Fabio J Pacheco; Gimena M J Zapata; Julieta M E Garcia; Carlos A Previale; Héctor E Cura; Winston J Craig Journal: Nutrients Date: 2016-07-09 Impact factor: 5.717